Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

DELAWARE DIAGNOSTIC LABS, LLC

NPI: 1144757212 · NEWARK, DE 19713 · Clinical Medical Laboratory · NPI assigned 05/19/2017

$8.53M
Total Medicaid Paid
265,283
Total Claims
149,470
Beneficiaries
55
Codes Billed
2018-05
First Month
2024-12
Last Month

Provider Details

Authorized OfficialWANG, BO (LAB DIRECTOR)
NPI Enumeration Date05/19/2017

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 1,270 $129K
2019 3,010 $286K
2020 13,802 $608K
2021 93,847 $2.63M
2022 93,622 $2.44M
2023 35,487 $1.36M
2024 24,245 $1.09M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 85,858 46,156 $4.15M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 19,364 16,409 $2.32M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 53,211 22,220 $386K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 59,601 26,459 $368K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 3,108 2,515 $317K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B 3,436 2,380 $289K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 2,297 2,038 $177K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 3,909 3,423 $159K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 3,389 2,894 $101K
87186 2,614 2,149 $53K
87481 2,696 2,221 $49K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc 2,028 969 $43K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 327 240 $41K
87640 3,085 2,506 $20K
87653 3,087 2,506 $20K
86409 687 627 $9K
86328 1,642 1,613 $8K
81002 4,902 4,112 $3K
80061 Lipid panel 947 767 $2K
83036 Hemoglobin; glycosylated (A1C) 661 502 $1K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 863 782 $1K
84443 Thyroid stimulating hormone (TSH) 521 475 $1K
80053 Comprehensive metabolic panel 667 592 $968.50
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 125 97 $864.49
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 96 75 $857.60
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 99 78 $857.60
36415 Collection of venous blood by venipuncture 2,164 1,715 $735.39
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 331 216 $725.08
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe 299 208 $718.20
87541 299 208 $718.20
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 89 58 $627.39
87641 334 243 $536.61
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 165 149 $436.13
86803 184 157 $252.12
86038 200 119 $179.40
80048 Basic metabolic panel (calcium, ionized) 252 214 $179.38
80076 211 198 $146.32
86431 203 119 $81.00
84436 130 118 $66.67
86140 204 119 $63.00
85610 98 92 $54.00
86704 80 78 $50.29
81001 54 48 $43.50
87340 80 78 $36.96
86706 80 78 $35.85
86708 80 78 $34.07
85027 69 54 $31.33
84479 80 78 $28.00
85730 80 78 $27.00
84439 67 64 $16.85
83655 14 13 $11.87
86592 14 12 $7.54
P9603 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled 155 44 $1.00
87486 12 12 $0.00
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 35 17 $0.00